June 25th 2025
A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage
Reflecting on the Real-World Use of Biologic Therapy in Asthma Management
Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
GSK's Nucala Comes Out Ahead in Comparison of Cinqair, Fasenra, Study Says
Intensive Care Unit Usage for Pneumonia Doubles Length of Hospital Stay
Health Organizations React to Rollback of Clean Power Plan Rules